IP Library Granted Patent US 8,119,780
Granted Patent B2
US 8,119,780 · App. 11/657,382 · Granted Feb 21, 2012

Chitosan-derivative compounds and methods of controlling microbial populations

Assignee: Synedgen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,780
App. No.
11/657,382
Granted
Feb 21, 2012
Kind
B2
Abstract

The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Claims (31)

1. A purified preparation comprising a chitosan-derivative compound of the following formula:

where m is 0.02-0.50; q is 0.50-0.01; s is 1; p+q+m=1; the percentage degree of functionalization is m/(1−q) ·100%; and X is selected from the group consisting of:

wherein the preparation is substantially free of compounds having a molecular weight of less than 5000 Da, and wherein the preparation is substantially free of polyarginine polymers.

2. The preparation as recited in claim 1 , wherein the compound comprises the following properties: a molecular weight between 25,000 and 350,000 Da, solubility at pH between 6.8 and 7.4, wherein said q is at least 0.20 and said functionalization is between 6% and 30%.

3. A purified preparation comprising a compound of the following formula:

where m is 0.02-0.50; q is 0.50-0.01; p+q+m=1 and percentage degree of functionalization is m/(1−q) ·100%;

wherein the preparation is substantially free of compounds having a molecular weight of less than 5000 Da, and wherein the preparation is substantially free of polyarginine polymers.

4. The preparation as recited in claim 3 , wherein the compound comprises the following properties: a molecular weight between 25,000 and 350,000 Da, solubility at pH between 6.8 and 7.4, wherein said q is at least 0.20 and said functionalization is between 6% and 30%.

5. A purified preparation comprising a chitosan-derivative compound of the following formula:

where m is 0.02-0.50; q is 0.50-0.01; s=1; p+q+m=1; and X′ is selected from the group consisting of:

where r is 1−6;

wherein the preparation is substantially free of compounds having a molecular weight of less than 5000 Da, and wherein the preparation is substantially free of polyarginine polymers.

6. A purified preparation comprising a chitosan-derivative compound of the following formula:

where m is 0.02-0.50; q is 0.50-0.01; p+q+m=1; and X″ is:

where r is 1−6.

7. A purified composition comprising chitosan-derivative compound of the following formula:

Where a=1; m is 0.02-0.50; q is 0.50-0.01; s=1; p+q+m=1; Z is a counterion; and X is selected from the group consisting of:

wherein the guanidine moiety is positively charged;

wherein the preparation is substantially free of compounds having a molecular weight of less than 5000 Da, and wherein the preparation is substantially free of polyarginine polymers.

8. The preparation as recited in claim 7 , wherein Z is selected from the group consisting of chloride, hydroxide, phosphate, carbonate, acetate, lactate, citrate, cinnamate, oxalate, and glutamate.

9. A purified preparation comprising a chitosan-derivative compound of the following formula:

where a=1; m is 0.02-0.50; q is 0.50-0.01; s=1; p+q+m=1; Z is a counterion; and X′ is selected from the group consisting of:

where r is 1−6, and wherein the guanidine moiety is positively charged;

wherein the preparation is substantially free of compounds having a molecular weight of less than 5000 Da, and wherein the preparation is substantially free of polyarginine polymers.

10. The preparation as recited in claim 9 , wherein Z selected from a group consisting of:

chloride, hydroxide, phosphate, carbonate, acetate, lactate, citrate, cinnamate, oxalate, and glutamate.

11. A purified preparation comprising a chitosan-derivative compound of the following formula:

where a=1; m is 0.02-0.50; q is 0.50-0.01; p+q+m=1; Z is a counterion; and X″ is:

where r is 1−6, and wherein the guanidine moiety is positively charged.

12. A preparation as recited in claim 11 , wherein Z is selected from a group consisting of:

chloride, hydroxide, phosphate, carbonate, acetate, lactate, citrate, cinnamate, oxalate, and glutamate.

Assignments (4)
CONFIRMATORY LICENSE Recorded Oct 11, 2022
From: SYNEDGEN, INC
To: UNITED STATES GOVERNMENT
Reel/Frame 061644/0084 →
CONFIRMATORY LICENSE Recorded Feb 23, 2010
From: SYNEDGEN, INC.
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 023974/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2009
From: BAKER, SHENDA; WIESMANN, WILLAM P.; RYAN, SHANNON
To: SYNEDGEN, INC.
Reel/Frame 023005/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2007
From: BAKER, SHENDA; RYAN, SHANNON; WIESMANN, WILLIAM
To: HAWAII CHITOPURE, INC.
Reel/Frame 019441/0135 →
Continuity (3)
Provisional Application 60810591 · Jun 2, 2006
Provisional Application 60838780 · Aug 18, 2006
Related Publication 20070281904A1 · Dec 6, 2007